Zymeworks Announces China Nmpa Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer
Zymeworks宣佈中國 Nmpa 接受生物製品執照申請,用於膽管癌二線治療的澤尼達莫泊
Zymeworks Announces China Nmpa Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer
Zymeworks宣佈中國 Nmpa 接受生物製品執照申請,用於膽管癌二線治療的澤尼達莫泊
譯文內容由第三人軟體翻譯。